arrow
D

Daniel M. Altmann

imperial college london
H指数:64
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID

作者更正:对长新冠机制和病理生理学理解的现状与未来展望

2026-07-230
OA
Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID

长新冠的机制和病理生理学理解的现状与未来展望

2026-04-290
OAAI
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immunemediated inflammatory diseases (VROOM study) a randomised, open label, superiority trial
2024-02-016
OAAI
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib

使用英夫利昔单抗或托法替尼的炎症性肠病患者对流感疫苗的抗体反应减弱

2023-11-062
OAAI
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

炎症性肠病患者在三剂新型冠状病毒肺炎疫苗 (VIP) 后中和针对SARS-CoV-2 Omicron BA.4/5和野生型病毒的抗体反应: 一项前瞻性、多中心、队列研究

2023-10-013
OAAI
Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network)

基孔肯雅病患者的自然史和治疗反应的多中心研究,重点是急性和慢性肌肉骨骼表现-基孔肯雅病临床和应用研究的研究方案 (REPLICK network)

2023-07-281
OAAI
Neutralising antibody potency against SARS-CoV-2 wild- type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2023-02-0125
OAAI
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study

免疫抑制的炎症性肠病患者在第三次疫苗剂量 (VIP) 后新型冠状病毒肺炎疫苗诱导的抗体和T细胞反应: 一项多中心,前瞻性,病例对照研究

2022-11-0141
OAAI